Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akorn, Inc.
Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
- Medical Devices
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Hi-Tech Pharmacal
- Oak Pharmaceuticals, Inc., VersaPharm